{"nctId":"NCT00613938","briefTitle":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.","startDateStruct":{"date":"2008-02"},"conditions":["Arthralgia","Bunion","Hallux Valgus","Pain"],"count":901,"armGroups":[{"label":"004","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"003","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: oxycodone"]},{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: Tapentadol (CG5503)"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: Tapentadol (CG5503)"]}],"interventions":[{"name":"Tapentadol (CG5503)","otherNames":[]},{"name":"Tapentadol (CG5503)","otherNames":[]},{"name":"oxycodone","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must undergo primary unilateral first metatarsal bunionectomy\n* Pain intensity must be moderate to severe following removal of a continuous popliteal sciatic block\n* Female patients must be postmenopausal, surgically sterile, or practicing an effective method of birth control if they are sexually active.\n\nExclusion Criteria:\n\n* Patients will be excluded from the study if they have a history of seizure disorder or epilepsy\n* History of malignancy within the past 2 years before starting the study\n* History of alcohol or drug abuse\n* Evidence of active infections that may spread to other areas of the body\n* Clinical laboratory values reflecting severe renal insufficiency\n* Moderately or severely impaired hepatic function\n* Currently treated with anticonvulsants, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), neuroleptics, or serotonin norepinephrine reuptake inhibitor (SNRI).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sum of Pain Intensity Difference Over 48 Hours (SPID48)","description":"The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (48 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine. A positive difference between the mean SPID48 for an active study drug and placebo would indicate a numerically larger analgesic effect for subjects dosed with active study drug than in the placebo group. A higher value in SPID indicates greater pain relief.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":"105.74"},{"groupId":"OG001","value":"122.2","spread":"98.66"},{"groupId":"OG002","value":"143.7","spread":"96.52"},{"groupId":"OG003","value":"140.3","spread":"99.52"}]}]}]},{"type":"SECONDARY","title":"Time to First Rescue Pain Medication Use.","description":"The effect of tapentadol (CG5503) IR on the time to the first use of rescue pain medication.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"The SPID at 12 Hours Relative to First Dose.","description":"The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (12 to 72 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine. A positive difference between the mean SPID12 for an active study drug and placebo would indicate a numerically larger analgesic effect for subjects dosed with active study drug than in the placebo group. A higher value in SPID indicates greater pain relief.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"20.7"},{"groupId":"OG001","value":"21.1","spread":"21.89"},{"groupId":"OG002","value":"26.0","spread":"23.11"},{"groupId":"OG003","value":"24.9","spread":"22.8"}]}]}]},{"type":"SECONDARY","title":"SPID at 24 Hours Relative to First Dose","description":"The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (12 to 72 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine. A positive difference between the mean SPID24 for an active study drug and placebo would indicate a numerically larger analgesic effect for subjects dosed with active study drug than in the placebo group. A higher value in SPID indicates greater pain relief.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"43.64"},{"groupId":"OG001","value":"45.4","spread":"45.73"},{"groupId":"OG002","value":"58.1","spread":"45.89"},{"groupId":"OG003","value":"53.8","spread":"46.69"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Reported Very Much Improved or Much Improved From Baseline in Patient Global Impression of Change to Day 3","description":"Ordinal measure indicating change from the start of treatment (On a scale of 7 = Very much Worse to 1 = very much improved) to endpoint at Day 3","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":null},{"groupId":"OG001","value":"83.2","spread":null},{"groupId":"OG002","value":"87.8","spread":null},{"groupId":"OG003","value":"86.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Pain Relief (TOTPAR)at 48 Hours","description":"Total Pain Relief (TOTPAR48) was defined as the weighted sum over all pain relief scores(PAR) from 0.5 hour to Hour 48, with the actual time elapsed from the previous PAR observation as the weight. A higher value in TOTPAR indicates greater pain relief.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.2","spread":"39.48"},{"groupId":"OG001","value":"96.6","spread":"37.39"},{"groupId":"OG002","value":"107.5","spread":"35.74"},{"groupId":"OG003","value":"105.2","spread":"37.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":69},"commonTop":["Nausea","Headache","Vomiting","Dizziness","Somnolence"]}}}